Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer

Eribulin mesylate (Halaven®) is a novel inhibitor of microtubule dynamics that has demonstrated a survival benefit in patients with locally recurrent or metastatic breast cancer who previously received at least two chemotherapeutic regimens including an anthracycline and a taxane. Although trastuzum...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukai, Hirofumi, Saeki, Toshiaki, Shimada, Ken, Naito, Yoichi, Matsubara, Nobuaki, Nakanishi, Tadashi, Obaishi, Hiroshi, Namiki, Masayuki, Sasaki, Yasutsuna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295025/
https://www.ncbi.nlm.nih.gov/pubmed/25242374
http://dx.doi.org/10.1007/s10637-014-0161-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295025/
https://www.ncbi.nlm.nih.gov/pubmed/25242374
http://dx.doi.org/10.1007/s10637-014-0161-y

Ejemplares similares